PMID- 23363074
OWN - NLM
STAT- MEDLINE
DCOM- 20140410
LR  - 20240503
IS  - 1365-2990 (Electronic)
IS  - 0305-1846 (Print)
IS  - 0305-1846 (Linking)
VI  - 39
IP  - 6
DP  - 2013 Oct
TI  - 1p/19q testing has no significance in the workup of glioblastomas.
PG  - 706-17
LID - 10.1111/nan.12031 [doi]
AB  - AIMS: To determine whether testing for isolated 1p or 19q losses, or as a 
      codeletion, has any significance in the workup of glioblastomas (GBMs). METHODS: 
      Upfront 1p/19q testing by fluorescence in situ hybridization (FISH) and/or 
      polymerase chain reaction (PCR)-based loss of heterozygosity (LOH) was done in 
      491 gliomas that were histologically diagnosed as GBMs. Outcomes were determined 
      and measured against 1p/19q results. RESULTS: Twenty-eight showed apparent 1p/19q 
      codeletion by either FISH and/or PCR-based LOH, but only 1/26 showed codeletion 
      by both tests. Over 90% of tumours with apparent codeletion by either FISH or LOH 
      also had 10q LOH and/or EGFR amplification, features inversely related to true 
      whole-arm 1p/19q codeletion. Furthermore, only 1/28 tumours demonstrated an R132H 
      IDH1 mutation. Neither 1p/19q codeletion by FISH nor LOH had an impact on GBM 
      survival. Isolated losses of 1p or 19q also had no impact on survival. 
      CONCLUSIONS: These data suggest that (i) 1p/19q testing is not useful on gliomas 
      that are histologically GBMs; (ii) codeletion testing should be reserved only for 
      cases with compatible morphology; and (iii) EGFR, 10q, and IDH1 testing can help 
      act as safeguards against a false-positive 1p/19q result.
CI  - (c) 2013 The Authors. Neuropathology and Applied Neurobiology (c) 2013 British 
      Neuropathological Society.
FAU - Clark, K H
AU  - Clark KH
AD  - Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.
FAU - Villano, J L
AU  - Villano JL
FAU - Nikiforova, M N
AU  - Nikiforova MN
FAU - Hamilton, R L
AU  - Hamilton RL
FAU - Horbinski, C
AU  - Horbinski C
LA  - eng
GR  - K08 CA155764/CA/NCI NIH HHS/United States
GR  - P20 RR020171/RR/NCRR NIH HHS/United States
GR  - 2P20 RR020171/RR/NCRR NIH HHS/United States
GR  - K08 CA155764-01A1/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Neuropathol Appl Neurobiol
JT  - Neuropathology and applied neurobiology
JID - 7609829
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain/pathology
MH  - Brain Neoplasms/*diagnosis/genetics/pathology
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 1
MH  - *Chromosomes, Human, Pair 19
MH  - Female
MH  - Genes, Neoplasm
MH  - Glioblastoma/*diagnosis/genetics/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Young Adult
PMC - PMC4095883
MID - NIHMS593525
OTO - NOTNLM
OT  - 1p/19q
OT  - FISH
OT  - LOH
OT  - glioblastoma
EDAT- 2013/02/01 06:00
MHDA- 2014/04/11 06:00
PMCR- 2014/10/01
CRDT- 2013/02/01 06:00
PHST- 2012/05/31 00:00 [received]
PHST- 2013/01/28 00:00 [accepted]
PHST- 2013/02/01 06:00 [entrez]
PHST- 2013/02/01 06:00 [pubmed]
PHST- 2014/04/11 06:00 [medline]
PHST- 2014/10/01 00:00 [pmc-release]
AID - 10.1111/nan.12031 [doi]
PST - ppublish
SO  - Neuropathol Appl Neurobiol. 2013 Oct;39(6):706-17. doi: 10.1111/nan.12031.